92 related articles for article (PubMed ID: 28823254)
21. [Detection of FLT3 gene and FLT3/ITD gene mutation in chronic myeloid leukemia and its significance].
Xu B; Tian H; Zhou SY
Ai Zheng; 2004 Oct; 23(10):1218-21. PubMed ID: 15473940
[TBL] [Abstract][Full Text] [Related]
22. [Differential analysis of BM cell morphology, immunophenotypic, cytogenetic characters and prognosis between myeloblastic and lymphoblastic crisis of CML].
Liu YL; Wang XN; Liu HS
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Jun; 22(3):629-33. PubMed ID: 24989266
[TBL] [Abstract][Full Text] [Related]
23. DNA methyltransferase 1 mediated aberrant methylation and silencing of SHP-1 gene in chronic myelogenous leukemia cells.
Li Y; Liu X; Guo X; Liu X; Luo J
Leuk Res; 2017 Jul; 58():9-13. PubMed ID: 28376405
[TBL] [Abstract][Full Text] [Related]
24. Molecular detection of survivin expression, antiapoptotic gene, and other prognostic markers, how they are correlated and how it could be of prognostic value in chronic myeloid leukemia patient.
Zhara M; Mourad H; Farouk G; Elbatch M; Ezzat S; Sami W
Egypt J Immunol; 2007; 14(2):51-62. PubMed ID: 20306657
[TBL] [Abstract][Full Text] [Related]
25. [An evaluation of the prognostic significance of antigen CD95(Fas/APO-1) expression on the cells of patients with a myelodysplastic syndrome, acute myeloid leukemia and chronic myeloleukemia].
Polosukhina ER; Kuznetsov SV; Logcheva NP; Zabotina TN; Tenuta MR; Shirin AD; Kaletin GI; Turkina AG; Tsvetaeva NV; Shishkin IuV; Kadagidze ZG; Khoroshko ND; Volkova MA; Baryshnikov AIu
Ter Arkh; 1998; 70(7):21-5. PubMed ID: 9742630
[TBL] [Abstract][Full Text] [Related]
26. Correlation between preferentially expressed antigen of melanoma and tumour necrosis factor-related apoptosis-inducing ligand gene expression in different types of leukaemia patients.
Zhang W; Chi K; Zhang Y; Ma B; Shi J; Chen Y; Lei P; Li Y; Sun K
Acta Haematol; 2013; 130(4):297-304. PubMed ID: 24008770
[TBL] [Abstract][Full Text] [Related]
27. PRAME mRNA levels in cases with chronic leukemia: Clinical importance and review of the literature.
Paydas S; Tanriverdi K; Yavuz S; Seydaoglu G
Leuk Res; 2007 Mar; 31(3):365-9. PubMed ID: 16914202
[TBL] [Abstract][Full Text] [Related]
28. Enhancing SHP-1 expression with 5-azacytidine may inhibit STAT3 activation and confer sensitivity in lestaurtinib (CEP-701)-resistant FLT3-ITD positive acute myeloid leukemia.
Al-Jamal HA; Mat Jusoh SA; Hassan R; Johan MF
BMC Cancer; 2015 Nov; 15():869. PubMed ID: 26547689
[TBL] [Abstract][Full Text] [Related]
29. [Genomic Instability in Acute Transformation of Chronic Myelogenous Leukemia].
Guo SQ; Li YH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Aug; 23(4):1199-202. PubMed ID: 26314473
[TBL] [Abstract][Full Text] [Related]
30. Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis.
Derderian PM; Kantarjian HM; Talpaz M; O'Brien S; Cork A; Estey E; Pierce S; Keating M
Am J Med; 1993 Jan; 94(1):69-74. PubMed ID: 8420302
[TBL] [Abstract][Full Text] [Related]
31. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
Cohen MH; Johnson JR; Pazdur R
Clin Cancer Res; 2005 Jan; 11(1):12-9. PubMed ID: 15671523
[TBL] [Abstract][Full Text] [Related]
32. Abnormality of c-kit oncoprotein in certain patients with chronic myelogenous leukemia--potential clinical significance.
Inokuchi K; Yamaguchi H; Tarusawa M; Futaki M; Hanawa H; Tanosaki S; Dan K
Leukemia; 2002 Feb; 16(2):170-7. PubMed ID: 11840282
[TBL] [Abstract][Full Text] [Related]
33. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
34. [Expression of bcl-2 gene in the evolution of chronic myelogenous leukemia to blast crisis and its implication].
Sui X; Su L; Chu J
Zhonghua Xue Ye Xue Za Zhi; 1999 Jan; 20(1):27-9. PubMed ID: 11498840
[TBL] [Abstract][Full Text] [Related]
35. Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-ex vivo culture.
Engelhardt M; Mackenzie K; Drullinsky P; Silver RT; Moore MA
Cancer Res; 2000 Feb; 60(3):610-7. PubMed ID: 10676644
[TBL] [Abstract][Full Text] [Related]
36. Analysis of P210bcr-abl tyrosine protein kinase activity in various subtypes of Philadelphia chromosome-positive cells from chronic myelogenous leukemia patients.
Maxwell SA; Kurzrock R; Parsons SJ; Talpaz M; Gallick GE; Kloetzer WS; Arlinghaus RB; Kouttab NM; Keating MJ; Gutterman JU
Cancer Res; 1987 Mar; 47(6):1731-9. PubMed ID: 2434223
[TBL] [Abstract][Full Text] [Related]
37. [Effect of 5-aza-CdR demethylation on expression of SHP-1 and C-kit genes in leukemia HL-60 cells].
Meng Z; Li YH; Wang DM; Luo JM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Dec; 22(6):1572-6. PubMed ID: 25543477
[TBL] [Abstract][Full Text] [Related]
38. Mixed phenotype (T/B/myeloid) extramedullary blast crisis as an initial presentation of chronic myelogenous leukemia.
Qing X; Qing A; Ji P; French SW; Mason H
Exp Mol Pathol; 2018 Apr; 104(2):130-133. PubMed ID: 29501750
[TBL] [Abstract][Full Text] [Related]
39. [Expression of growth-factor independence 1 in patients with leukemia and its significance].
Wang TT; Chen ZX; Cen JN; He J; Sheng HJ; Yao L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Aug; 18(4):834-7. PubMed ID: 20723283
[TBL] [Abstract][Full Text] [Related]
40. [One of the Mechanisms in Blastic Transformation of Chronic Myeloid Leukemia: Epigenetics Abnormality--Review].
Meng Z; Li YH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):250-3. PubMed ID: 26913431
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
